NASDAQ$CLDX
Celldex Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported business and financial highlights for the fourth quarter and year ended December 31, 2020.
Celldex Therapeutics reported a net loss of $21.9 million for the fourth quarter of 2020, with total revenue of $3.8 million. The company's cash, cash equivalents, and marketable securities totaled $194.4 million as of December 31, 2020, which they believe is sufficient to fund planned operations through 2023. They also had significant progress across their pipeline, especially with CDX-0159.
- Observed an 80% complete response rate in a Phase 1b study of CDX-0159 in chronic inducible urticaria.
- Expanded the CDX-0159 study to include patients with cholinergic urticaria.
- Initiated a Phase 1 study of CDX-527, the first candidate from their bispecific platform.
- Recorded a non-cash partial impairment charge of $14.5 million related to the TAM program IPR&D asset.
Headline financials
Revenue & EPS history
Celldex · Revenue · Quarterly
$3.79M
Forward guidance
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2020 are sufficient to meet estimated working capital requirements and fund planned operations through 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+1.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+1.7%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+35.2%
Q4 2023
Best reaction
-21.5%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.2% | -7.0% | -16.8% | |
| Q4 2025 | -0.6% | -6.1% | -1.7% | |
| Q3 2025 | +7.6% | +12.7% | +23.2% | |
| Q1 2025 | +2.2% | -0.4% | -0.5% | |
| Q4 2024 | -1.6% | -3.1% | -3.4% | |
| Q3 2024 | +4.1% | +3.1% | +5.3% | |
| Q2 2024 | +2.7% | +3.8% | +36.5% | |
| Q1 2024 | -0.8% | -6.2% | -22.4% | |
| Q4 2023 | +35.2% | +37.4% | +10.7% | |
| Q3 2023 | +10.2% | +23.1% | +35.9% | |
| Q2 2023 | -6.5% | -7.4% | -13.3% | |
| Q1 2023 | +5.8% | +5.3% | +5.5% | |
| Q4 2022 | +7.9% | +8.7% | -17.4% | |
| Q3 2022 | +9.4% | +5.6% | +7.5% | |
| Q2 2022 | -3.8% | +1.7% | -17.7% | |
| Q1 2022 | -10.3% | -10.6% | -23.4% | |
| Q4 2021 | +4.7% | +0.5% | +14.7% | |
| Q3 2021 | +0.6% | -7.6% | -18.1% | |
| Q2 2021 | +6.2% | +3.7% | +20.9% | |
| Q1 2021 | -1.3% | -3.3% | +0.8% | |
| Q4 2020 | -16.9% | -4.0% | +30.4% | |
| Q3 2020 | +1.4% | +9.6% | +10.3% | |
| Q2 2020 | -3.5% | -12.3% | -7.5% | |
| Q1 2020 | +0.4% | +0.4% | +29.4% | |
| Q4 2019 | +3.4% | -7.3% | +68.2% | |
| Q3 2019 | -2.5% | -5.0% | -7.9% | |
| Q2 2019 | +6.2% | +1.4% | +2.9% | |
| Q1 2019 | -6.6% | -15.4% | -36.1% | |
| Q4 2018 | +9.0% | +4.3% | -7.3% | |
| Q3 2018 | +15.2% | +3.0% | -21.2% | |
| Q2 2018 | +0.0% | -6.7% | +2.2% | |
| Q1 2018 | -5.2% | -7.8% | -15.6% | |
| Q4 2017 | +14.1% | +17.0% | -17.4% | |
| Q3 2017 | +15.5% | +14.7% | +23.1% | |
| Q2 2017 | +2.4% | -0.8% | +11.7% | |
| Q1 2017 | +0.7% | +2.9% | -23.5% | |
| Q4 2016 | +1.8% | +2.1% | -2.1% | |
| Q3 2016 | +22.3% | +39.8% | +21.7% | |
| Q2 2016 | +0.4% | -4.3% | -21.5% | |
| Q1 2016 | -8.9% | — | — | |
| Q4 2015 | +10.9% | — | — | |
| Q3 2015 | +5.4% | — | — | |
| Q2 2015 | -21.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | -21.5% | — | — | |
| Q2 2014 | +4.0% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | -5.2% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +13.3% | — | — | |
| Q3 2012 | +5.9% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q3 2011 | -3.6% | — | — | |
| Q2 2011 | -15.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | +7.6% | — | — | |
| Q2 2010 | -3.9% | — | — | |
| Q1 2010 | -2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro